Progression to AIDS in SIV-infected rhesus macaques is associated with distinct KIR and MHC class I polymorphisms and NK cell dysfunction

Christina Albrecht†1, Dörthe Malzahn2†, Markus Brameier†, Meike Hermes†, Aftab A. Ansari3† and Lutz Walter2† *

† Primate Genetics Laboratory, German Primate Center, Leibniz-Institute for Primate Research, Göttingen, Germany
2 Department of Genetic Epidemiology, University Medical Center, Georg-August-University, Göttingen, Germany
3 Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA

INTRODUCTION

Natural killer (NK) cells are large bone marrow-derived granular lymphocytes that perform essential functions in the innate immune response against various pathogens and in the priming of adaptive immunity. The main effector functions of NK cells are target cell killing and cytokine release, which are regulated via integration of signals derived from stimulatory and inhibitory receptors expressed on the cell surface of these lymphocytes. NK cells are important effector cells to combat infection with viruses (1), including human and simian immunodeficiency viruses (SIVs) (2–4).

Killer cell immunoglobulin-like receptors (KIR) regulate the activity of natural killer (NK) cells and have been shown to be associated with susceptibility to a number of human infectious diseases. Here, we analyzed NK cell function and genetic associations in a cohort of 52 rhesus macaques experimentally infected with SIVmac and subsequently stratified into high viral load (HVL) and low viral load (LVL) plasma viral loads at set point. This stratification coincided with fast (HVL) and slow (LVL) disease progression indicated by the disease course and critical clinical parameters including CD4+ T cell counts. HVL animals revealed sustained proliferation of NK cells but distinct loss of peripheral blood NK cell numbers and lytic function. Genetic analyses revealed that KIR genes 3DL06, 3DS05, and 3DL10 as well as 3DSW08, 3DLW03, and 3DSW09 are correlated, most likely due to underlying haplotypes. SIV-infection outcome associated with presence of transcripts for two inhibitory KIR genes (KIR3DL02, KIR3DL10) and three activating KIR genes (KIR3DSW08, KIR3DS02, KIR3DS05). Presence of KIR3DL02 and KIR3DSW08 was associated with LVL outcome, whereas presence of KIR3DS02 was associated with HVL outcome. Furthermore, we identified epistasis between KIR and MHC class I alleles as the transcript presence of the correlated genes KIR3DL05, KIR3DS05, and KIR3DL10 increased HVL risk when Mamu-B*012 transcripts were also present or when Mamu-A1*001 transcripts were absent. These genetic associations were mirrored by changes in the numbers, the level of proliferation, and lytic capabilities of NK cells as well as overall survival time and gastro-intestinal tissue viral load.

Keywords: virus infection, killer cell immunoglobulin-like receptors, MHC class I ligands, genetic polymorphism, epistasis, rhesus macaque SIV infection model, AIDS
of the inhibitory KIR2DL2 with HLA-C1 presenting mutated peptides (14).

Simian immunodeficiency virus (SIV)-infected rhesus macaques represent an established and important animal model to study the mechanisms of HIV infection. SIV-induced syndromes and the temporally diverse progression to AIDS of SIV-infected rhesus macaques are remarkably similar to human HIV-1 infection with variable disease outcome ranging from spontaneous control of plasma viremia (elite controllers, about 5–20% of infected individuals) to uncontrolled viremia and rapid disease course (fast progressors, about 5–10%). These polarized clinical outcomes during persistent viremia in experimentally infected rhesus macaques suggest genetic variability may play a critical role in SIV containment. Rhesus macaque KIR genes are considered as candidate genes that contribute to different clinical outcomes as they are at least as diverse as human KIR genes (15–18). Indeed, in SIV-infected rhesus macaques, copy number variations (CNV) of the inhibitory KIR3DL05 gene were shown to be associated with fast progression to AIDS, whereas CNVs of activating KIR3DS genes were associated with control of virus replication (19, 20). However, it is clear that the studies of the beneficial or detrimental combinations of KIR and MHC class I polymorphisms are in their infancy and much has yet to be learnt about these associations. Further, it is unclear whether changes in the level of expression of KIRs occur during the course of SIV infection and whether these changes contribute to disease pathogenesis.

Herein, we demonstrate that NK cells in SIV-infected rhesus macaques with rapid disease progression and high viral load (HVL) show sustained proliferation but less lytic activity, followed by a dramatic depletion of NK cells from the peripheral blood. This functional impairment is accompanied by changes of transcription of five KIR genes (inhibitory: KIR3DL02, KIR3DL10; activating: KIR3DSW08, KIR3DS02, KIR3DS05). Presence of the correlated KIR3DL05, KIR3DS05, and KIR3DL10 genes combined with presence of Manmu-B*012 or with lack of Manmu-A1*001 was more frequently found in animals rapidly progressing to disease, and animals with such KIR/MHC class I combinations displayed higher gastro-intestinal tissue (GIT) viral loads and shorter survival times.

MATERIALS AND METHODS

ETHICAL STATEMENT

Juvenile to adult male rhesus macaques (Macaca mulatta) of Indian origin were used for the studies reported herein. All animals were born and maintained at the Yerkes National Primate Center (Atlanta, GA, USA) in accordance with the regulations of the Committee on the Care and Use of Laboratory Animal Resources, National Research Council and the Department of Health and Human Service guideline titled Guide for the Care and Use of Laboratory Animals, and with the Weatherall report (21). None of the animals, blood and tissue samples originated from the German Primate Center. The animals were fed monkey diet (Purina) supplemented daily with fresh fruit or vegetables and water ad libitum. Additional enrichment including the delivery of appropriate safe toys is provided and overseen by the Yerkes enrichment staff and animal health is monitored daily by the animal care staff and veterinary personnel, available 24/7. Monkeys are caged in socially compatible same sex pairs to facilitate social enhancement and well-being. Monkeys showing signs of sustained weight loss, disease or distress are subject to clinical diagnosis based on symptoms and then provided either standard dietary supplementation analgesics and/or chemotherapy. Monkeys whose symptoms cannot be alleviated using standard dietary supplementation, analgesics and/or chemotherapy were humanely euthanized using an overdose of barbiturates according to the guidelines of the American Veterinary Medical Association. The studies reported herein were performed under IACUC protocol #20011186 “Innate immunity in SIV infection” which was reviewed and approved by the Emory University IACUC. It has been assigned the IACUC protocol number “YER-20011186-082414GA.” The Yerkes National Primate Research Center has been fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International since 1985. All experiments were reviewed and approved by the Emory institutional animal use and care as well as biosafety review Committees.

SIV INFECTION OF RHESUS MACAQUES

This study was conducted on a cohort of 52 juvenile to adult male rhesus macaques that were infected intravenously with 1000 TCID50 of either SIVmac251 (n = 5) or SIVmac239 (n = 47) grown in con-A blast cultures from normal rhesus macaques. Statistical analyses in this report results were fairly robust when excluding the five SIVmac251 infected animals (data not shown). On the other hand including these animals notably increased statistical power by increasing the sample size. Based on viral loads following achievement of stable set points (that correlated with absolute peripheral blood CD4+ T cell levels, and clinical characteristics including hemogram values, weight gain/loss and blood chemistries, see Table 1) the cohort was stratified into rhesus macaques with low plasma viral load (LVL (n = 24); <105 mean ± S.D. viral copies/mL of plasma; slow progression to AIDS) and rhesus macaques with high plasma viral load (HVL (n = 28); >105 mean ± SD viral copies/mL of plasma; rapid progression to AIDS). Figure 1 shows box and whiskers plots of viral loads at set point, indicating that the virus copy numbers are significantly different (p = 0.0008) and non-overlapping between the two strata, and Figure 2 underlines the distinctly different survival times between HVL and LVL. Blood samples from each monkey were obtained three times prior to SIV infection to derive average baseline absolute numbers of the various cell lineages. The monkeys were bled once per week post infection for 6–8 weeks and then biweekly for an additional 2 months and monthly thereafter to monitor plasma viral copy numbers and absolute numbers of lymphoid cell subsets. Cellular viral loads in aliquots of PBMC and colorectal biopsy tissue samples were monitored using a technique standardized in our lab that included negative and positive controls.

SPECIMEN COLLECTION, MONONUCLEAR CELLS ISOLATION, VIRUS QUANTITATION

Peripheral blood mononuclear cells (PBMC) were isolated from heparinized whole blood using standard Ficoll-Hyphae centrifugation procedure. The cell count and cell viability were
Table 1 | Overview of the macaque cohort (n = 52).

| Outcome | LVL, n = 24 | SIVmac251, n = 2 | HVL, n = 28 | SIVmac251, n = 3 |
|---------|-------------|-----------------|-------------|----------------|
| Virus*  | SIVmac239, n = 22 | SIVmac251, n = 2 | SIVmac239, n = 25 | SIVmac251, n = 3 |
| Summary statistic | Individual data | Summary statistic | Individual data |
| Median (range) | mm34 | Median (range) | mm19 | mm25 | mm27 |
| Sex | 100% male | Male | 100% male | Male | Male | Male |
| Age at pre-infection (days) | 1492 (median) | 1680 | 2061 | 1555 (median) | 1695 | 1810 | 1801 |
| Intravenously injected viral dose: | 1000 TCID50 per animal |
| At pre-infection | 1364 (552–2018) | 2134 | 1567 | 1350 (601–2121) | 1884 | 1887 | 2139 |
| At ≥26 weeks p.i. | 918.0 (477–1519) | 667 | 612 | 150.5 (66–742) | 109 | 73 | 109 |
| Viral load in peripheral blood | | | | |
| At peak | 2.2 × 10^6 (4.2 × 10^5–32.6 × 10^5) | 0.3 × 10^6 | 1.1 × 10^6 | 15.0 × 10^5 (2.8 × 10^5–104.0 × 10^5) | 10.8 × 10^5 | 21.0 × 10^5 | 6.7 × 10^6 |
| At set point | 2.4 × 10^5 (20–70.2 × 10^5) | 4.0 × 10^5 | 1.5 × 10^5 | 3.3 × 10^6 (0.3 × 10^6–36.8 × 10^6) | 3.0 × 10^6 | 4.0 × 10^6 | 2.0 × 10^6 |

| Outcomes of interest |
|----------------------|
| Survival time (in month, censored times indicated by >) |
| Median | >200 month | >73 | >156 | 38 month | 151 | >14 | 54 |
| First event | 146 month | 15 month |
| Last event | – | 70 month |
| # Events | 1 event | 26 events |
| Viral load in gastro-intestinal tissue | 9 (3–27) | Missing | 6 | 22 (8–92) | 19 | 46 | 27 |

| Number of NK cells |
|---------------------|
| At pre-infection | 860.5 (668–1229) | 831 | 729 | 884.0 (612–1242) | 933 | 893 | 789 |
| >26 weeks p.i. | 639.5 (348–834) | 332 | 673 | 94.0 (32–143) | 87 | 124 | 143 |
| %Ki67+ NK cells | 6.7 (4.2–10.3) | 5.4 | 2.7 | 5.8 (2.9–8.3) | 73 | 5.6 | 73 |
| 8–12 weeks p.i. | 9.3 (4.5–15.6) | 9.3 | 8.4 | 46.7 (29.6–77.6) | 45.6 | 35.6 | 19.5 |
| %CD107+ positive NK cells | 18.3 (4.9–37.2) | Missing | 22.5 | 23.7 (6.9–42.8) | 32.7 | 13.9 | 19.3 |
| Pre-infection | 18.6 (12.3–276) | Missing | 15.4 | 16.8 (72–33.9) | 13.2 | 14.3 | 6.9 |
| Acute infection | 16.2 (8.1–30.1) | Missing | 16.9 | 8.0 (0.1–24.6) | 6.9 | 2.1 | 0.4 |

While animals were comparable at pre-infection, the cohort separated into two distinct subgroups (LVL, HVL) regarding set point viral loads. All other clinical parameters consistently indicate slow (LVL) or fast (HVL) disease progression.

*Virus strain did not associate with infection outcome (HVL outcome: p = 1.00, survival time: p = 0.591).

performed using the trypan blue dye technique. The cell concentrations were adjusted to 1 × 10^6 cells/mL in complete RPMI1640 media. Aliquots of EDTA plasma were obtained prior to and at varying intervals following SIV infection and sent on dry ice to Siemens Laboratories (Siemens, Berkeley, CA, USA) for quantitating plasma SIV levels using the branched DNA assay. Data
obtained are illustrated as plasma VL per milliliter of plasma. For the quantitation of pro-viral DNA load, aliquots of the unfractionated PBMCs and cells obtained from the colorectal gut biopsy tissues collected at various times post infection were used to isolate total genomic DNA using the Qiagen DNAeasy kit (Qiagen, Valencia, CA, USA). For purposes of brevity, only the data for pro-viral DNA levels on cells isolated from rectal biopsy samples obtained during viral load set point (week 8 p.i.) are shown. An aliquot of the genomic DNA isolated was used to quantitate the amount of DNA per sample, and the number of viral copies per nanogram of DNA was determined using our standardized laboratory protocol for quantitation of SIV gag (22, 23). The SIV1C cell line that has a single copy of SIV DNA per cell was used as a control for the pro-viral DNA analysis. The sensitivity of the assay was one infected cell per million. The quantitation of viral RNA was performed using RNA extraction, RNase free primer pairs, and real-time PCR utilizing SYBR Green for iCycler kit as previously described (24). The sensitivity of this assay was 10 viral copies/mL.

POLYCHROMATIC FLOW CYTOMETRY AND FLUOROCHROME-CONJUGATED MONOCLONAL ANTIBODIES

Various fluorochrome-conjugated monoclonal antibodies (mAbs) were used in appropriate combinations to stain aliquots of the PBMCs. The mAbs utilized were purchased from BD Biosciences (San Jose, CA, USA) and included Alexa700-anti-CD3 (clone SP34-2), PerCP, Pac Blue or V450-conjugated anti-CD4 (clone L200), FITC or V500-anti-CD8 (clones SK1, RPA-T8), FITC-anti-CD14 (clone M5E2), PerCP-Cy5.5 or APC-Cy7-anti-CD16 (clone 5G8), APC-Cy7 or PeE-Cy7-anti-CD20 (clones 2H7, L27), PE-Cy7-anti-CD56 (clone NCAM16.2), APC-anti-CD123 (clone
7G3), PerCP-Cy5.5-anti-HLA-DR (clone L243), FITC or PE-conjugated Ki67 (clone B56), Alexa700 or PE-Cy5-anti-CD107a (clone H4A3). The PE-anti-NKG2A (clone Z199) was purchased from Beckman Coulter (Brea, CA, USA) and FITC-anti-human γδTCR (clone SA6.E9) from Invitrogen. Standard gating strategies were utilized to identify CD3+CD4+αβ cells, CD3+CD8+αβ cells, CD3+γδ cells, CD3−CD20+ B cells, CD3−CD8−NKG2A−CD14+ monocytes, as well as CD3−CD8−NKG2A+ NK cells and respective subsets based on CD16 and CD56 expression (25, 26). The cells were incubated with the appropriate combination of fluorochrome-conjugated antibodies for 30 min covered with aluminum foil and kept at 4°C. The cells were then washed twice with FACS buffer and resuspended in FACS buffer containing 2% paraformaldehyde and kept under aluminum foil until analyzed using a LSRII flow cytometer (BD Immunocytometry Division, Mountain View, CA, USA). A minimum of 100,000 events were examined per sample and data were analyzed using FlowJo software (TreeStar, Ashland, OR, USA). An aliquot of the blood sample was utilized to perform complete blood count and the values utilized to calculate absolute number of each cell lineage.

**NK CELL FUNCTION ANALYSIS**

An aliquot of the PBMC sample to be analyzed for NK functional activity was co-cultured in vitro with HLA class I-devoid K562 or 721.221 cells at an effector/target ratio of 10:1 for 6 h at 37°C in a humidified 7% CO2 incubator in the presence of Brefeldin-A.
(5 ug/mL, Sigma-Aldrich), Monensin (6 ug/mL, Golgi-Stop, BD Biosciences) and anti-CD107a (clone LAMP1, BD Biosciences). Media throughout consisted of RPMI 1640 supplemented with 10% fetal calf serum, 2 mM l-glutamine, 100 units/mL penicillin and 100 ug/mL streptomycin. Each assay included an aliquot of the same PBMC cultured alone (negative control) and an aliquot of the same PBMC incubated with 1.25 ug/mL phorbol-12-myristate 13-acetate (PMA, Sigma-Aldrich) and 0.25 ug/mL ionomycin (Sigma Aldrich) as a positive control. Only experiments in which the overlap between forward and reverse reads covers around one third (180 nt) of the sequenced part of the KIR gene transcript. We also tested the KIR profile allowing four or six mismatches (i.e., 8 or 12 in forward + reverse), but this lead to ambiguous alignments for some KIR gene transcripts, i.e., matching of single reads to multiple KIR genes (data not shown). Frequencies of filtered forward and reverse reads were summed up and the relative contribution of each KIR transcript was compared to the total number of KIR transcripts identified in each individual. The MHC class I and KIR gene transcript sequencing data of the entire 52 rhesus macaques are shown in Tables S1 and S2 in Supplementary Material.

STATISTICAL ANALYSES

The various statistical software programs used included SAS, R, and GraphPad Prism 6.

Time-course of NK cell numbers from 8–12 weeks p.i. to 26 to >26 weeks p.i. was analyzed by longitudinal linear regression, testing statistical interaction between covariates time and group (HVL, LVL) (see Figure 2). Difference of means of % Ki67 + NK cells at 8–12 weeks p.i. between HVL and LVL animals was examined by t-test; and the lytic function of NK cells was analyzed in HVL and LVL by repeated measures ANOVA (Figure 3, testing change of mean%CD107a-positive NK cells over time, i.e., from pre- to acute and chronic infection).

Target HVL outcome was analyzed by logistic regression, survival times by Cox regression, and NK cell number and corresponding functional data as well as viral loads in gut tissue by linear regression models, testing KIR main effects (Table 3, multiple or single KIR covariates as indicated) and KIR–MHC class I epistasis (see Table 4 and Figures 5 and 6; statistical interaction models contained a KIR and a MHC-I covariate, respectively). Furthermore, for the main target HVL outcome, we compared a multiple model (multi-KIR) with univariate analyses (single-KIR) (see Table 3, Table 4).
At 26 weeks p.i. and beyond, the mean absolute number of NK cells in high and comparable across HVL and LVL was jointly analyzed (first column). In contrast to single-KIR analyses, the multi-KIR model estimates mutually adjusted KIR main effects and accounts for correlations between KIR genes (a priori excluded were KIR genes that had small strata size or strong correlations with other KIR genes). In addition, the frequency of KIR transcript sequence reads at pre- and acute-infection (where NK cell numbers were high and comparable across HVL and LVL) was jointly analyzed in KIR-positive animals as longitudinal metric target by longitudinal rank-sum test (28) for association with HVL outcome (Table 3, last column). Rank-sum testing ensured test validity given that KIR transcript frequencies had skewed distributions. The rank-sum test resembles a heteroscedastic 1-way repeated measures ANOVA with factor HVL outcome on the longitudinal rank-order data of observed KIR transcript frequencies. Longitudinal analyses incorporated all animals that had any trait data (number of animals is indicated in Table 3; no omission of animals with incomplete follow-up and no imputation of missing values). We used SAS procedure mixed for longitudinal linear regression on% CD107a-positive NK cells and R package nparLD for longitudinal rank-sum testing of relative KIR transcript amounts (Table 3).

Association between MHC class I alleles and HVL outcome was tested by Fisher’s exact tests (see Table S3 in Supplementary Material). Finally, the probability to obtain K \( p \) values \( \leq 0.05 \) for a family of M association tests with HVL outcome was estimated under the null hypothesis of no associations, based on 10,000 data replicates with randomly permuted HVL/LVL group assignment.

RESULTS

NK CELL NUMBERS, PROLIFERATION, AND ACTIVITY DURING SIV INFECTION

The cohort of rhesus macaques \( (n = 52) \) was experimentally infected with SIV (SIVmac) and subsequently stratified into animals with “low viral load” (LVL) and “high viral load” (HVL) based on viral load at set point (Figure 1A). Disease progressed much faster in HVL compared to LVL as indicated by absolute levels of blood CD4+ T cell counts and other clinical parameters (see Table 1 and Materials and Methods for details). The marked differences between HVL and LVL animals are further exemplified by a Kaplan–Meier survival curve (hazard ratio 80.7, \( p = 0.00002 \); Figure 2A). Table 1 shows a summary of the cohort and relevant data that are also displayed in Figures 1–3.

The disease course in HVL and LVL animals displays the typical marked \( (p < 0.0001) \) decline of CD4+ T cell counts in both strata (Figure 1B). Whereas the numbers of CD8+ T cells were rather similar (Figure 1B), we observed differences in blood NK cell numbers in LVL and HVL animals (Figure 2B). An increase of NK cell numbers during the acute phase of SIV infection (2–6 weeks p.i.) was followed by a steady decline in both strata. However, in contrast to LVL animals, HVL animals displayed a more marked decline in the number of NK cells during the chronic phase of infection by \( -30.6 \) per week (95% CI [−36.3, −24.9]; \( p < 0.0001 \)). At 26 weeks p.i. and beyond, the mean absolute number of NK cells per µL blood in the HVL stratum was lower by \( -547.2 \) (95% CI [−608.6, −485.9]; \( p < 0.0001 \)) compared to LVL animals. The proliferation of NK cells (% Ki67+) peaked during the acute phase of infection (2 weeks p.i.) in both strata (Figure 2B). Interestingly, the percentage of Ki67+ NK cells rapidly declined in LVL animals and reached pre-infection levels at 8–12 weeks p.i. with a mean value of 9.7% (95% CI [8.7, 10.8]), whereas in contrast a significantly higher amount of proliferating NK cells was observed in HVL animals as long as 8–12 weeks p.i. (t-test, \( p < 0.0001 \)) with a mean value of 46.4% (95% CI [42.3, 50.4]). Ki67+ NK cells that was sustained significantly \( (p < 0.0001) \) at high levels during the chronic phase of infection. Thus, blood NK cells in HVL animals had higher proliferation activity than in LVL animals particularly at time points 4–12 weeks p.i., a time interval when NK cell numbers of both strata are still comparable.

Next we determined the capacity of NK cells from LVL and HVL animals to lyse MHC class I-deficient cells in a degranulation assay using samples obtained at different time points post infection. The percentage of CD107a+ NK cells during transition from pre-infection to acute and chronic phases declined in HVL animals (repeated measures ANOVA, \( p = 0.0001 \)), but remained stable in LVL animals \( (p = 0.3086) \) (Figure 3).

Collectively, these data demonstrate that NK cells from animals with fast progression to AIDS and shorter survival times had sustained proliferation after SIV infection, but lost their lytic capability and constantly decreased in number following peak viral load.

KIR HETEROGENEITY IN THE RHESUS MACAQUE COHORT

As KIR proteins essentially regulate the activity of NK cells, we detected no transcripts of the KIR gene in our cohort. The most frequently transcribed KIR gene in our cohort was KIR3DL01 (92%, \( n = 48 \)), KIR genes particularly rarely transcribed were KIR3DL04 (2%, \( n = 1 \)), KIR3DL06 (4%, \( n = 2 \)), KIR3DS01 (12%, \( n = 6 \)), KIR3DS04 (10%, \( n = 5 \)), and KIR3DS06 (13%, \( n = 7 \)). Similar to the cohort analyzed by Moreland and co-workers \( (18) \), we detected no transcripts of the KIR3DS07 gene in our cohort. Thus, the KIR gene diversity in our cohort is comparable to other cohorts.

ASSOCIATION OF KIR AND MHC CLASS I POLYMORPHISMS WITH PROGRESSION TO AIDS

We initially tested whether the presence of individual KIR genes is correlated, for example due to close genetic linkage, which has hitherto not been determined for rhesus macaque KIR genes. Of particular interest for subsequent genetic association analyses with SIV infection outcome are strong correlations as well as distinctly different correlations in HVL compared to LVL. The latter may occur in the vicinity of functionally relevant genes when specific haplotypes associate with HVL outcome. As can be seen in Table 2, correlation between KIR3DL05–KIR3DS05–KIR3DL10 and KIR3DS08–KIR3DL03–KIR3DSW09 strongly suggests that these are neighboring genes (in the given order). Stronger correlation in HVL compared to LVL animals may indicate some functional relevance of these gene sets to infection outcome and differences in KIR haplotypes.
FIGURE 4 | KIR genes in SIV infected rhesus macaques with slow (LVL, n = 24) and rapid (HVL, n = 28) progression to AIDS (A,B). Relative percentage of animals displaying the KIR transcript (bar height) with 95% confidence limits (error bars). The number n of animals transcribing the respective KIR gene is given below the bars. (A) Complete cohort of n = 52 rhesus macaques. Boxes indicate correlated KIR genes (KIR3DL10–KIR3DS05–KIR3DL05; KIR3DSW08–KIR3DLW03–KIR3DSW09; see Table 2). (B) Cohort stratified into HVL (n = 28) and LVL (n = 24) animals. (C) KIR transcript frequencies of animals transcribing the KIR3DL02 or the KIR3DL05 gene before (pre) and during different time points after infection (acute, chronic).
Table 2 | Correlation of KIR transcript presence at pre-infection.

| Table 2 | Correlation of KIR transcript presence at pre-infection. |
|---------|----------------------------------------------------------|
|         | Whole cohort (n = 52) | HVL animals (n = 28) | LVL animals (n = 24) |
| KIR3DS05 | KIR3DLW03 | KIR3DS05 | KIR3DLW03 | KIR3DS05 | KIR3DLW03 |
| KIR3DL10a | 0.74 (p = 5.2 × 10⁻¹⁰) | 0.70 (p = 4.3 × 10⁻⁵) | 0.75 (p = 2.9 × 10⁻⁵) |
| KIR3DL05a | 0.42 (p = 0.0023) | 0.84 (p = 3.9 × 10⁻⁵) | −0.04 (p = 0.84) |
| KIR3DSW08b | 0.56 (p = 1.6 × 10⁻⁵) | 0.74 (p = 9.6 × 10⁻⁶) | 0.45 (p = 0.027) |
| KIR3DSW09b | 0.35 (p = 0.012) | 0.61 (p = 8.0 × 10⁻⁵) | 0.12 (p = 0.57) |

Displayed correlations (Pearson estimate, p value) were strong enough to have p ≤ 10⁻¹⁰ in HVL or LVL (significances in bold, Bonferroni: p ≤ 0.05/240 = 2.08 × 10⁻⁸ for testing pairwise correlations of 16 KIRs in HVL and LVL). KIR3DL04 (2%), KIR3DL06 (4%), KIR3DL01 (92%) were not tested.

a KIR3DL10 tended to correlate with KIR3DL05 in the whole cohort (r = 0.35, p = 0.013) and in HVL (r = 0.55, p = 0.003) but not in LVL (r = 0.10, p = 0.65).

b KIR3DSW08, KIR3DSW09 were uncorrelated in the whole cohort (r = −0.01, p = 0.92) with opposing but non-significant tendencies in HVL (r = 0.18, p = 0.36) and LVL (r = −0.19, p = 0.39).

For KIR association analyses (Table 3) we converted levels of KIR transcript at pre-infection into binary variables that were subsequently used as covariate(s). Target traits for association analyses included HVL outcome (logistic regression), survival time (Cox regression), NK cell number and functional data (linear regression). KIR effect estimates were mutually adjusted in a single multi-KIR model of HVL outcome, which was the main target (Table 3, first column, significances in bold, Bonferroni: p ≤ 0.05/240 = 2.08 × 10⁻⁸ for testing pairwise correlations of 16 KIRs in HVL and LVL). KIR3DL04 (2%), KIR3DL06 (4%), KIR3DL01 (92%) were not tested.

For KIR association analyses (Table 3) we converted levels of KIR transcript at pre-infection into binary variables that were subsequently used as covariate(s). Target traits for association analyses included HVL outcome (logistic regression), survival time (Cox regression), NK cell number and functional data (linear regression). KIR effect estimates were mutually adjusted in a single multi-KIR model of HVL outcome, which was the main target (Table 3, first column, significances in bold, Bonferroni: p ≤ 0.05/240 = 2.08 × 10⁻⁸ for testing pairwise correlations of 16 KIRs in HVL and LVL). KIR3DL04 (2%), KIR3DL06 (4%), KIR3DL01 (92%) were not tested.

For KIR association analyses (Table 3) we converted levels of KIR transcript at pre-infection into binary variables that were subsequently used as covariate(s). Target traits for association analyses included HVL outcome (logistic regression), survival time (Cox regression), NK cell number and functional data (linear regression). KIR effect estimates were mutually adjusted in a single multi-KIR model of HVL outcome, which was the main target (Table 3, first column, significances in bold, Bonferroni: p ≤ 0.05/240 = 2.08 × 10⁻⁸ for testing pairwise correlations of 16 KIRs in HVL and LVL). KIR3DL04 (2%), KIR3DL06 (4%), KIR3DL01 (92%) were not tested.
Table 3 | KIR association with HVL outcome, survival and NK cell function.

| Target trait | HVL outcomea | Survivalb | Number of NK cells | %Ki67+ NK cellsc | %CD107a-positive NK cellsd | Frequency of KIR transcript sequence reads |
|--------------|-------------|-----------|-------------------|-----------------|---------------------------|------------------------------------------|
|               | Multi-KIR               | Single-KIR | Single-KIR At ≥ 26 weeks p.i. | Single-KIR At 8–12 weeks p.i. | Single-KIR Longitudinal time-course | Longitudinal test (P) |
| KIR          | OR (P)      | OR (P)    | HR (P)           | Δ (P)          | Δ (P)          | Δ (P)          | Rank-sum test (P) |
| 1D           | 0.60 (0.656) | 1.21 (0.735) | 1.12 (0.777) | —0.69 (0.993) | 0.4 (0.947) | —1.0 (0.755) | (0.464) |
| 3DL01        | — —         | — —       | — —             | — —            | — —           | — —           | — —           |
| 3DL02        | 0.01 (0.0007) | 0.13 (0.002) | 0.24 (0.005) | 220.7 (0.006) | —15.7 (0.006) | 6.7 (0.033) | (0.033) |
| 3DL04        | — —         | — —       | — —             | — —            | — —           | — —           | — —           |
| 3DL05(2)     | 0.09 (0.037) | 1.21 (0.735) | 1.29 (0.536) | —48.7 (0.546) | 1.6 (0.773) | 1.1 (0.850) | (0.022) |
| 3DS05(9)     | — —         | 2.83 (0.068) | 1.84 (0.127) | —118.8 (0.128) | 7.7 (0.174) | —4.7 (0.172) | (0.228) |
| 3DL10(9)     | 0.98 (0.989) | 3.75 (0.025) | 1.96 (0.088) | —180.5 (0.017) | 10.9 (0.056) | —6.4 (0.035) | (0.521) |
| 3DL06        | — —         | — —       | — —             | — —            | — —           | — —           | — —           |
| 3DL07        | 5.26 (0.166) | 1.43 (0.562) | 1.48 (0.401) | —27.6 (0.750) | 5.8 (0.330) | 1.5 (0.931) | (0.291) |
| 3DL08        | 17.24 (0.211) | 1.06 (0.921) | 1.11 (0.798) | 15.9 (0.841) | 0.5 (0.933) | —1.9 (0.456) | (0.150) |
| 3DL11        | 0.47 (0.452) | 0.41 (0.137) | 0.47 (0.083) | 116.4 (0.155) | —8.2 (0.165) | 3.3 (0.410) | (0.688) |
| 3DS01        | — —         | 0.15 (0.0504) | 0.20 (0.041) | 243.9 (0.042) | —15.5 (0.076) | 5.1 (0.367) | (—) |
| 3DS02        | 46.50 (0.008) | 2.88 (0.118) | 2.96 (0.043) | —169.0 (0.065) | 11.6 (0.056) | —3.8 (0.379) | (0.277) |
| 3DS03        | 0.06 (0.238) | 1.26 (0.711) | 1.08 (0.861) | —53.1 (0.548) | 3.3 (0.610) | 1.3 (0.695) | (0.669) |
| 3DS04        | — —         | 0.56 (0.541) | 0.59 (0.448) | 109.1 (0.410) | 3.2 (0.741) | 3.2 (0.638) | (—) |
| 3DS06        | — —         | 2.50 (0.283) | 2.07 (0.182) | —140.9 (0.216) | 3.5 (0.656) | —3.4 (0.514) | (—) |
| 3DSW08(9)    | 0.10 (0.038) | 0.21 (0.025) | 0.29 (0.020) | 222.8 (0.014) | —13.2 (0.025) | 1.6 (0.640) | (—) |
| 3DW09(3)     | — —         | 0.55 (0.371) | 0.62 (0.322) | 90.3 (0.330) | —9.2 (0.127) | —1.8 (0.268) | (0.772) |
| 3DSW09(9)    | 0.02 (0.084) | 0.66 (0.574) | 0.74 (0.570) | 120.9 (0.240) | —8.0 (0.210) | —1.8 (0.353) | (0.732) |

P values ≤ 0.05 in bold (significance in the multi-KIR model). Rare KIR3DL04, KIR3DL06 (n ≤ 2 with this KIR) were not analyzed. The most frequent KIR3DL01 (n = 4 without this KIR) was only analyzed for frequency of KIR transcript sequence reads.

aLogistic regression for target HVL outcome, with a single KIR or multiple KIR covariate(s): odds ratio (OR, < 1 for protective KIR) and p value (P) (likelihood ratio test, χ² statistic). ORs in the multi-KIR model are mutually adjusted within a single model for KIRs with strata sizes ≥ 9 animals; excluding 3DS05, 3DLW03 due to strong correlations (see Table 2).

bCox proportional hazards model with a single KIR covariate: hazard ratio (HR, < 1 for protective KIR) and p value (P) (likelihood ratio test, χ² statistic).

cLinear regression for target number of NK cells, with a single KIR covariate: P value (P) (t statistic) and KIR effect Δ (difference of trait means; Δ > 0 indicates a protective KIR that associates with higher NK cell numbers at ≥ 26 weeks p.i.).

dLinear regression for target %Ki67+ NK cells, with a single KIR covariate: P value (P) (t statistic) and KIR effect Δ (difference of trait means; Δ > 0 indicates a protective KIR that associates with increased NK cell proliferation at 8–12 weeks p.i.).
Table 4 | KIR3DS05, KIR3DL10 epistasis with MHC class I alleles on HVL risk.

| MHC class I | KIR3DS05 | Epistasis | P* | KIR3DL10 | Epistasis | P* |
|-------------|----------|-----------|-----|----------|-----------|-----|
|             | OR_MHC (p value) | OR_KIR (p value) | OR_MHCxKIR (p value) |         | OR_MHC (p value) | OR_KIR (p value) | OR_MHCxKIR (p value) |
| A*001       | 1.50 (p = 0.622)  | 21.60 (p = 0.009)  | 0.035 (p = 0.020)  | 0.041 | 1.40 (p = 0.654)  | 21.60 (p = 0.009)  | 0.036 (p = 0.024)  |
| A*004       | 11.00 (p = 0.015) | 7.33 (p = 0.034)  | 0.20 (p = 0.224)  |       | 3.64 (p = 0.101)  | 3.25 (p = 0.167)  | 1.10 (p = 0.942)  |
| B*012       | 0.50 (p = 0.471)  | 1.25 (p = 0.755)  | 10.00 (p = 0.087) |       | 0.40 (p = 0.320)  | 1.20 (p = 0.811)  |       |
| B*048       | 2.67 (p = 0.283)  | 4.40 (p = 0.044)  | 0.26 (p = 0.272)  |       | 1.30 (p = 0.745)  | 3.66 (p = 0.084)  | 1.03 (p = 0.984)  |
| B*057       | 6.42 (p = 0.040)  | 6.60 (p = 0.028)  | 0.17 (p = 0.153)  |       | 2.60 (p = 0.221)  | 4.33 (p = 0.089)  | 0.58 (p = 0.659)  |
| B*072       | 10.29 (p = 0.047) | 20.01 (p = 0.014) | 0.054 (p = 0.043) |       | 3.00 (p = 0.179)  | 8.00 (p = 0.029)  | 0.29 (p = 0.330)  |

Displayed are all model term estimates (main effects and epistasis: odds ratio’s OR (p values), p ≤ 0.05 in bold) for twelve models of KIR–MHC class I polymorphism pairings. The two correlated KIR risk genes KIR3DS05 and KIR3DL10 were coded for transcript presence at pre-infection. The MHC class I alleles were coded for transcript presence, did not correlate significantly, and were frequent with sufficient strata sizes. The simultaneous risk estimates OR, OR, and OR quantify HVL risk of MHC-I-negative animals (OR), HVL risk of KIR in MHC-I-negative animals (OR), and epistatic effects for coincident presence of KIR and MHC-I (OR). Animals with coincident MHC-I and KIR presence have the HVL risk OR. OR and OR compared to animals with coincident MHC-I and KIR absence. *Probability that – under the null-hypothesis of no epistasis and no genetic associations – two or more p ≤ 0.05 for six epistasis tests of MHC class I alleles with a KIR gene. This probability was estimated based on 10,000 permutations of the HVL/LVL group assignment.

that were previously found to co-occur on distinct MHC class I haplotypes (29, 30). It should be noted that rhesus macaque MHC class I haplotypes display extensive CNV of Mamu-B genes (29, 31–33). We found Mamu-A1*004 transcribes more frequently in the HVL than in the LVL stratum (OR 3.7, p = 0.029) (see Table S3 in Supplementary Material), and in accord with previous studies also Mamu-A1*001 (OR 0.4, p = 0.163) and the rare allele Mamu-B*008 (OR 0.0, p = 0.208) more frequently in the LVL than in the HVL stratum (not reaching significance for the latter two).

**ANALYSES OF COMBINATIONS OF KIR AND MHC CLASS I POLYMORPHISMS AND PROGRESSION TO AIDS**

KIR3DL1/3DS1 in combination with HLA-Bw4-80I alleles (in particular HLA-B*57) are associated with slow progression to AIDS in human HIV infection (8, 9, 11, 34). Knowledge of the contribution of similar combinations of KIR and MHC class I alleles is currently not available in the model of SIVmac infection of rhesus macaques.

Sufficient strata sizes for epistasis analyses of KIR and MHC class I transcript presence were available for MHC class I alleles with cohort frequencies between 34.6 and 46.2% when combined with KIR genes with about 50% sample frequency. Of these KIR genes, the correlated putative risk genes KIR3DS05, KIR3DL10 were the most interesting. Analyses of epistasis on HVL outcome (Table 4) consistently revealed higher power for KIR3DS05 as well as deleterious effects of KIR3DS05 and Mamu-A1*004. Epistasis test p values in Table 4 were not particularly significant. However, observing two (out of six) p ≤ 0.05 only had a probability p = 0.041 under the null-hypothesis of no epistasis and no genetic associations. Moreover, model estimates of KIR3DS05 and KIR3DL10 with Mamu-A1*001 were remarkably consistent. They indicate that the presence of KIR3DS05 or KIR3DL10 transcripts in Mamu-A1*001-negative animals associated with a 21.6-times higher HVL risk (p = 0.009). However, presence of Mamu-A1*001 transcripts annulled this detrimental effect of KIR3DS05, KIR3DL10 (epistasis p ≤ 0.024; yielding an odds ratio of 1.1 for combined presence of Mamu-A1*001 with KIR3DS05 or KIR3DL10).

Whereas Mamu-B*012 per se did not influence disease outcome according to our analysis (Table 4), there was a tendency of a higher HVL risk in animals with coincident presence of Mamu-B*012 with KIR3DS05 or KIR3DL10 transcripts (potential epistasis; note also the consistency of model estimates of Mamu-B*012 with KIR3DS05 and KIR3DL10). Furthermore, it is of interest to note that Mamu-A1*004, Mamu-B*012, and Mamu-B*057 co-occur on MHC class I haplotypes that were previously reported for other rhesus macaques of Indian origin with rapid or intermediate SIV-disease progression (30).

While ORs had considerable estimation uncertainty (as is common in epistasis analyses), the epistasis of Mamu-A1*001 and Mamu-B*012 with KIR3DS05 and KIR3DL10 on HVL outcome was also observed for viral copy numbers in GIT (Figure 5), and for survival time (Figure 6). In Mamu-A1*001-negative animals, viral copy numbers in GIT were particularly high in animals expressing KIR3DS05 and KIR3DL10: 23.9 (p = 0.0081) or 21.8 (p = 0.017) more copies on average, respectively (Figure 5A). A similar trend can be seen in animals expressing the correlated KIR3DS05 gene (17.2, p = 0.076). However, presence of Mamu-A1*001 transcripts is associated with an effect that is contrary to the KIR3DS05, KIR3DL05, and KIR3DL10 main effects. In animals expressing KIR3DS05, the presence of Mamu-A1*001 transcripts was associated with decreased viral copy numbers by −31.6 on average (p = 0.015). Similar trends were seen in animals expressing KIR3DL05 or KIR3DL0, where the presence of Mamu-A1*001 transcripts coincided with decreased viral copy numbers by −17.3 (p = 0.19) or −20.6 (p = 0.13) on average (Figure 5A). Coincident presence of Mamu-B*012 with KIR3DL05, KIR3DS05 or KIR3DL10 transcripts resulted in 32.8 (p = 0.0173), 34.7 (p = 0.0091) or
FIGURE 5 | Epistasis of the correlated KIR3DL05, KIR3DS05, KIR3DL10 genes with Mamu-A1*001 and Mamu-B*012 on viral copy numbers in GIT. The boxplots of viral copy numbers stratify for presence (+) and absence (−) of Mamu-A1*001 or Mamu-B012 and the respective KIR transcripts. Sample sizes n are displayed at the bottom of the graphs. (A) Illustrated are the KIR main effects (directly observed in Mamu-A1*001-negative animals) and the epistatic effects of Mamu-A1*001 in KIR3DL05-, KIR3DS05- or KIR3DL10-positive animals. (B) The epistasis model with Mamu-B*012 revealed consistent epistatic effects but no KIR main effects, suggesting that the KIR main effects (see Table 3 and this figure, part A) may be marginal effects from an epistasis with Mamu-B*012.

35.1 (p = 0.0074) more viral copies on average, respectively (Figure 5B), confirming the suspected epistasis. Interestingly, no KIR main effects were seen in the epistasis models with Mamu-B*012 (Figure 5B). This suggests that the KIR3DS05, KIR3DL10 main effects in the single-KIR analyses in Table 3 as well as in Figure 5A may be marginal effects from an epistasis with Mamu-B*012.

Figure 6 illustrates the fact that the presence of KIR3DL10 transcripts when combined with lack of Mamu-A1*001 or with presence of Mamu-B*012 transcripts also led to shorter survival times, confirming the epistasis. Highly similar results were obtained for the correlated but the more rare KIR3DS05 gene and for KIR3DL05 (not shown), albeit with weaker power.

DISCUSSION
Our understanding of the biology of NK cells continues to evolve. Besides its killer function, data supporting the ability of cells within this lineage to become educated, acquire memory and participate in a number of immune regulatory function are accumulating (35–39). Consequently, the role of NK cells in HIV-1 infection
and its corresponding non-human primate model has attracted much attention in AIDS research (20, 34, 40, 41). Particular attention in human HIV-1 infection has been paid to genetic factors that modulate NK-cell function and susceptibility to disease. Key determinants of NK-cell activation are the highly polymorphic KIR receptors and their MHC class I ligands. While human KIR3DL1/S1 allotypes in combination with HLA-B allotypes carrying the serological Bw4 epitope with an isoleucine residue at position 80 (HLA-Bw4-80I) were identified as protective, such combinations were hitherto not known in the rhesus macaque SIV infection model.

Based on viral load at set point that correlated well with clinical course (time to the development of AIDS) and absolute levels of peripheral blood CD4+ T cells, we grouped rhesus macaques experimentally infected with SIVmac into “HVL” and “LVL” strata. In contrast to LVL animals that had a relatively benign disease course, we found a progressive loss of peripheral blood NK-cell numbers after peak viraemia in animals rapidly succumbing to SIV-mediated disease (HVL). Further distinguishing HVL from LVL animals is a considerably higher percentage of proliferating (% Ki67+ and CD16+ T cells, leading to failure of CD8+ T cells, we grouped rhesus macaques experimentally infected with SIVmac into “HVL” and “LVL” strata. In contrast to LVL animals that had a relatively benign disease course, we found a progressive loss of peripheral blood NK-cell numbers after peak viraemia in animals rapidly succumbing to SIV-mediated disease (HVL). Further distinguishing HVL from LVL animals is a considerably higher percentage of proliferating (% Ki67+ T cells, indicating dysfunction of NK cells. Dysfunctional NK cells have been reported in HIV-1-infected individuals (42–44) and in SIV-infected rhesus macaques (45). Recent studies highlighted an important role of NK cells in the regulation of cytotoxic activity as evidenced by decreased CD107a-positive NK cells (Figure 2B), however, is not associated with increased cytokine secretion. Indeed, it has been proposed that cytotoxic CD8+ NK cells have a limited role in the control of SIV (48). According to our data, this regulation obviously preferentially affects the CD4+ as compared with the CD8+ T-cell subset (Figure 1) and might be particularly effective in HVL animals 4–12 weeks p.i., a time point when NK cell numbers are still high and about 50% of these NK cells are proliferating (activated) in contrast to only 10–20% NK cells in the LVL cohort.

Control of lentiviruses might be influenced by NK cells at the local viral entry site with an important contribution by a NK cell subset that is uniquely present in such mucosal tissues (49). Indeed, rhesus macaques infected intra-rectally or intra-vaginally with SIVmac251 showed some functional differences of mucosal and blood NK cells, including a higher lytic capacity (% CD107a expression) of mucosal NK cells (50). However, whether differences in KIR expression are evident and responsible for these phenomena is currently not known.

We hypothesized that the observed functional differences of NK cells and the different disease outcomes are due to KIR and MHC class I polymorphisms. However, comprehensive molecular typing of KIR and MHC class I polymorphisms at the DNA level is extremely complicated in rhesus macaques due to large expansions of both gene families and extensive copy-number variations as well as an absence of detailed genomic information of haplotypes (only single KIR and MHC class I haplotypes are completely sequenced). Therefore, we used published next-generation sequencing approaches to determine transcripts of both rhesus macaque gene families (18,27) and analyzed the risk correlations were consistently for KIR3DL01 and was in all single KIR3DSW08 (whole cohort: p = 0.156; non-significant after Bonferroni correction), and most probably KIR3DS01 genes as protective factors in the rhesus macaque SIV infection model (Table 3; Figure 4). The activating KIR3DS02 gene was detected as a risk gene, but only when KIR correlations were accounted for (multi-KIR model, Table 3). Of note, KIR3DS02 had a certain correlation with the cluster KIR3DL05–KIR3DS05–KIR3DL10, in particular with KIR3DL05 (whole cohort: r = 0.41, p = 0.0031; HVL stratum: r = 0.54, p = 0.0034; LVL stratum: r = 0.30, p = 0.156; non-significant after Bonferroni correction), and was in all single KIR analysis consistent with this KIR gene cluster (Table 3). While no specific ligand has so far been reported for KIR3DL02, a suggested ligand for KIR3DSV08 is Mamu-A3*13 (51). In accord with this, the Mamu-A*3*13 allele (formerly designated Mamu-A1*13) was reported to be associated with longer survival times of SIV-infected rhesus macaques (52) and is present on MHC haplotypes that were associated with slow, but also intermediate and rapid SIV disease progression (30). Unfortu- nately, frequencies of KIR3DL02 and KIR3DSV08 in the cohort (see Figure 4B, Table S1 in Supplementary Material) were not high enough to include both in the epistasis analyses. In addition, we had to exclude rare KIR genes (KIR3DL04, KIR3DL06; n ≤ 2, ≤ 3.8%) or KIR genes with high frequency (KIR3DL01;
n = 48, 92.3%). Nevertheless, as about half of the animals (46%) belong to the LVL group, rare or very frequent genes are not expected to be responsible for the observed differences between LVL and HVL animals. Of note, the relative amounts of KIR transcripts were higher in LVL for the KIR3DL02 gene and higher in HVL animals for the KIR3DL05 gene, respectively (Figure 4C), supporting the aforementioned findings. Although we cannot exclude that these KIR genes show increased transcription, a more likely explanation for this observation appears to be a higher percentage of cells expressing these KIR genes, probably due to clonal expansions (T cells) or education (NK cells). As we analyzed transcripts from PBMCs, this might pertain to both KIR-expressing NK and T cell subsets. Furthermore, the association of KIR genes with HVL outcome was mirrored in clinical (survival time) and functional (decline of blood NK cell numbers, sustained NK cell proliferation, and loss of NK cell lytic function) parameters.

How can these associations of KIR genes with SIV disease outcome be explained? In general, involvement of inhibitory KIR expressed on cytolytic cells (NK, CD8+ T, γδ T) may lower the cytolytic activity of these cells toward infected cells (negative effects), but reduced activity may also result in less immune pathology (positive effect). Similarly, involvement of activating KIR proteins may enhance killing of SIV-infected cells by such cytolytic cells (positive effect), but may also evoke immune pathology (negative effect). Thus, beneficial and detrimental effects can be found for both inhibitory and activating KIR proteins and presence/absence polymorphisms in the individual’s genotype certainly influence the outcome. In the case of SIV infection we identified genes associated with a beneficial (KIR3DL02, KIR3DSW08) and others with a detrimental (KIR3DL05, KIR3DL10, KIR3DS02) outcome of infection.

In (uninfected) rhesus macaques, we previously identified KIR expression on 1–3% of CD4+ T cells, 4–25% of αβ CD8+ T cells, and 9–58% of γδ T cells (26). The role of KIR expression on T cell subsets is not as elaborated as for NK cells. It was previously shown that expression of inhibitory KIR on tumor-infiltrating human CD8+ T cells was associated with decreased effector functions such as interruption of TCR-mediated signaling and failure to rearrange the actin cytoskeleton (53). KIR expression is particularly seen in memory CD8+ T cells, but the exact role of KIR proteins in the formation of these cells is not known.

As strong linkage disequilibrium of KIR genes can perturb identification of corresponding risk genes in disease association studies, we analyzed coincidence of KIR gene transcripts and analyzed respective correlations. Indeed, KIR3DL05, KIR3DS05, and KIR3DL10 as well as KIR3DSW08, KIR3DLW03, and KIR3DSW09 correlated, respectively (Table 2). These correlations are most likely due to underlying haplotypes. Unfortunately, this assumption could not be tested as only a single rhesus macaque KIR haplotype is completely sequenced (54). Yet, these correlations complicated the analyses for KIR3DL05–KIR3DS05–KIR3DL10 as none of these genes show consistent significant associations in all analyses such as for example KIR3DL02. However, for each of the various parameters tested at least one member of this KIR gene cluster shows significant (or borderline significance) association, indicating that cluster 3DL05–3DS05–3DL10 contains a risk KIR gene. Support for this assumption comes from epistasis analyses of KIR with MHC class I alleles. KIR3DS05 and KIR3DL10 only increased the risk of HVL outcome when Mamu-A1*001 was absent (odds ratio 21.6), but not when Mamu-A1*001 was present (odds ratio 1.1). This finding is particularly interesting as Mamu-A1*001 is a well-known protective MHC class I allotype (55, 56) and a ligand of KIR3DL05 (51, 57) and KIR3DS05 (51). A summary of the known KIR and MHC class I interactions is shown in Table 5. As Mamu-A1*001 is a well-known protective allele, the observed protective effect in epistasis analysis might also be attributed to this MHC class I allele only and not to epistasis with KIR genes. However, this appears rather unlikely given that (1) 35.7% (10/28) of the HVL animals indeed express Mamu-A1*001 (Table S2 in Supplementary Material) and are not protected, and (2) the mere presence of this MHC class I allele does not protect from high viral load (Figure 5A, compare for example 3DS05-/A1*001–with 3DS05-/A1*001+). Furthermore, statistical epistasis tests do not become significant because of consistent variant (KIR and MHC) effects but rather when such variant effects are statistically not independent (i.e., not additive for viral load). Thus, Mamu-A1*001 does not have a consistent protective effect across KIR strata and its effect obviously depends on epistasis with KIR genes. Further, the combined presence of Mamu-B*012 and KIR3DS05 (OR 10.0, p = 0.087) or KIR3DL10 (OR 25.0, p = 0.036) suggests a higher risk of HVL outcome. The biological significance of such epistasis is indicated by significant differences in gastro-intestinal viral load (Figure 5B) and in significantly shorter survival times of KIR3DL10-positive animals that lack Mamu-A1*001 or express Mamu-B*012 (Figure 6). Furthermore, epistasis analyses of HVL outcome, GIT viral load, and survival times suggest that KIR3DS05 and KIR3DL10 may not be detrimental per se for disease outcome, but only in combined presence with Mamu-B*012. In accord with our finding of Mamu-B*012 being a risk factor, this allele was particularly found on several haplotypes that were associated with rapid progression to AIDS (30). Some of the limitations of our analyses that are outlined above might be overcome in future SIV infection studies involving more animals and when complete KIR haplotypes are sequenced.

In a previous report Hellmann and colleagues (20) used Mamu-A1*001-negative SIV-infected rhesus macaques and found that variations in copy numbers of activating KIR genes associated with control of SIV replication. Yet, the individual gene(s) underlying this control were not further specified. In accord with the data of Hellmann and colleagues, we identified the activating KIR3DSW08 gene (and most likely KIR3DS01 as well) as protective in our cohort. The identification of the activating KIR3DS05 as a risk

Table 5 | Known interactions of rhesus macaque KIR and MHC class I ligands.

| KIR       | Interacting Mamu class I | Reference |
|-----------|--------------------------|-----------|
| KIR3DL01  | Mamu-B with Bw4 motif    | (58)      |
| KIR3DLW03 | Mamu-A1 alleles *001, *008; *011 | (51) |
| KIR3DL05  | Mamu-A1 alleles *001, *002; Mamu-A3*13 | (51, 57) |
| KIR3DL11  | Mamu-A1*008              | (51)      |
| KIR3DS05  | Mamu-A1 alleles *001, *011 | (51)      |
factor in combination with Mamu-B*12 underscores the necessity to study associations at the level of individual genes as well as epistasis of the involved genes.

We conclude that a comprehensive survey of genetic factors that influence SIV-infection outcome needs both MHC class I and KIR genes in addition to other known anti-viral factors such as TRIM5. Such detailed knowledge is important when analyzing respective data of SIV-infected rhesus macaques to exclude any potential bias introduced by these disease-relevant genetic factors.

ACKNOWLEDGMENTS
The authors are grateful for expert technical assistance of Nico Westphal and Ann E. Mayne and thank Dr. Libby Guethlein (Stanford University, Stanford, USA) for providing the rhesus macaque KIR gene database.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at http://www.frontiersin.org/10.3389/fimmu.2014.00600/abstract

REFERENCES
1. Lanier LL. Evolutionary struggles between NK cells and viruses. Nat Rev Immunol (2008) 8(4):259–68. doi:10.1038/nri2276
2. Chang JJ, Altfeld M. Innate immune activation in primary HIV-1 infection. J Infect Dis (2010) 202(Suppl 2):S297–301. doi:10.1086/655657
3. Bashirova AA, Thomas R, Carrington M. HLA/KIR restriction of HIV: surviving the fittest. Annu Rev Immunol (2011) 29:295–317. doi:10.1146/annurev-immunol-031210-101332
4. Bostik P, Takahashi Y, Mayne AE, Ansari AA. Innate immune natural killer cells and their role in HIV and SIV infection. HIV Ther (2010) 4:483–504. doi:10.2217/HIV.10.28
5. Parham P, Abi-Rached L, Matevosyan L, Moesta AK, Norman PJ, Older Aguilar AM, et al. Primate-specific regulation of natural killer cells. J Med Primatol (2010) 39:194–212. doi:10.1111/j.1600-0641.2010.00432.x
6. Wagner W. Major histocompatibility complex class-I interacting natural killer cell receptors of nonhuman primates. J Immunol (2011) 3:236–41. doi:10.1159/000323932
7. Martin MP, Carrington M. Immunogenetics of HIV disease. Immunol Rev (2013) 254:245–64. doi:10.1111/imr.12071
8. Martin MP, Gao X, Lee J-H, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B slows the progression to AIDS. Nat Genet (2002) 32:429–34. doi:10.1038/ng2834
9. Song R, Lisovsky I, Lebouché B, Reut I-P, Brunet J, Bernard NF. HIV Protective KIR3D1L/S1-HLA-B genotypes influence NK cell-mediated inhibition of HIV replication in autologous CD4 T targets. PLoS Pathog (2014) 10:e1003867. doi:10.1371/journal.ppat.1003867
10. Yawata M, Yawata N, Draghi M, Little AM, Partheniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med (2006) 203:633–45. doi:10.1084/jem.20051884
11. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Perryra O, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 39:273–80. doi:10.1038/ng3035
12. Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg ES, et al. HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute human immunodeficiency virus type 1 infection. J Virol (2009) 83:6798–805. doi:10.1128/JVI.00256-09
13. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM, et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature (2011) 476:96–100. doi:10.1038/nature10237
14. Kruse PH, Rosner C, Walter L. Characterization of rhesus macaque KIR genotypes and haplotypes. Immunogenetics (2010) 62:281–93. doi:10.1007/s00251-010-0435-4
15. Blokhuis JH, van der Wiel MK, Dowxdas GGM, Bontrop RE. The mosaic of KIR haplotypes in rhesus macaques. Immunogenetics (2010) 62:295–306. doi:10.1007/s00251-010-0434-3
16. Blokhuis JH, van der Wiel MK, Dowxdas GGM, Bontrop RE. The extreme plasticity of killer cell Ig-like receptor (KIR) haplotypes differentiates rhesus macaques from humans. Eur J Immunol (2011) 41:2719–28. doi:10.1002/eji.201141621
17. Moreland AJ, Guethlein LA, Reeves RK, Bromam KW, Johnson RP, Parham P, et al. Characterization of killer immunoglobulin-like receptor genetics and comprehensive genotyping by pyrosequencing in rhesus macaques. BMC Genomics (2011) 12:295. doi:10.1186/1471-2164-12-295
18. Bostik P, Kobjajroaen I, Tang W, Villinger F, Pereira LE, Little DM, et al. Decreased NK cell frequency and function is associated with increased risk of KIR3DL allele polymorphism in simian immunodeficiency virus-infected rhesus macaques with high viral loads. J Immunol (2009) 182:3638–49. doi:10.4049/jimmunol.0803580
19. Hellmann I, Lim S-Y, Gelman RS, Letvin NL. Association of activating KIR copy number variation of NK cells with containment of SIV replication in rhesus monkeys. PLoS Pathog (2011) 7:e1002436. doi:10.1371/journal.ppat.1002436
20. Pereira LE, Johnson RP, Ansari AA. Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. Cell Immunol (2008) 254:10–9. doi:10.1016/j.cellimm.2008.06.006
21. Webster RL, Johnson RP. Delineation of multiple subpopulations of natural killer cells in rhesus macaques. Immunology (2005) 115:206–14. doi:10.1111/j.1365-2657.2005.02147.x
22. Hermes M, Albrecht C, Schrod A, Braemier M, Walter L. Expression patterns of KIR and HLA subtypes against HIV-1. PLoS One (2013) 8:e64936. doi:10.1371/journal.pone.0064936
23. O’Leary CE, Wiseman RW, Karl JA, Bimmer BN, Lank SM, Tuschler JI, et al. Identification of novel MHC class I sequences in pig-tailed macaques by amplicon pyrosequencing and full-length cDNA cloning and sequencing. Immunogenetics (2009) 61:689–701. doi:10.1007/s00251-009-0397-4
24. Malzahn D, Schillert A, Muller M, Bickelhorer H. The longitudinal nonparametric test as a new tool to explore gene-gene and gene-time effects in cohorts. Genet Epidemiol (2010) 34:649–78. doi:10.1002/gepi.20500
25. Doyxdas GGM, de Groot N, Otting N, de Vos-Rouweler AJM, Bolijn MJ, Heijmans CMC, et al. Haplootype diversity generated by ancient recombination-like events in the MHC of Indian rhesus macaques. Immunogenetics (2013) 65:569–84. doi:10.1007/s00251-013-0707-8
26. Stuermerm U, Siddiqui R, Suh Y-S, Platter M, Leuchte N, Meyer H, et al. Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques. Genes Immun (2008) 9:69–80. doi:10.1038/sj.gene.6564448
27. Otting N, Heijmans CMC, Noort RC, de Groot NG, Doyxdas GGM, van Rood JJ, et al. Unparalleled complexity of the MHC class I region in rhesus macaques. Proc Natl Acad Sci U S A (2005) 102:16261–6. doi:10.1073/pnas.0409804102
28. Otting N, Heijmans CMC, van der Wiel M, de Groot NG, Doyxdas GGM, Bontrop RE. A snapshot of the Mamu-B genes and their allelic repertoire in rhesus macaques of Chinese origin. Immunogenetics (2008) 60:507–14. doi:10.1007/s00251-008-0311-5
29. Wiseman RW, Karl JA, Bimmer BN, O’Leary CE, Lank SM, Tuschler JI, et al. Major histocompatibility complex genotyping with massively parallel pyrosequencing. Nat Med (2009) 15:1322–6. doi:10.1038/nm.2038

www.frontiersin.org November 2014 | Volume 5 | Article 600 | 15
34. Carrington M, Alter G. Innate immune control of HIV. Cold Spring Harb Perspect Med (2012) 2:a007670. doi: 10.1101/cshperspect.a007670

35. Sun JC, Beilke IN, Lanier LL. Adaptive immune features of natural killer cells. *Nature* (2009) 457:7229–57. doi: 10.1038/nature07665

36. Paust S, Andrian von UH. Natural killer cell memory. *Nat Immunol* (2011) 13:501–8. doi: 10.1038/ni.2032

37. Narni-Mancini E, Jaeger BN, Bernat C, Fenis A, Kung S, De Gassart A, et al. Tuning of natural killer cell reactivity by NKp46 and Helios calibrates T cell responses. *Science* (2012) 335:544–8. doi: 10.1126/science.1215621

38. Waggoner SN, Cornberg M, Seulin PK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. *Nature* (2012) 481(7381):394–8. doi: 10.1038/nature10624

39. Eibharra T, Jonsson AH, Yokoyama WM. Natural killer cell licensing in mice with inducible expression of MHC class I. *Proc Natl Acad Sci U S A* (2013) 110(42):17323–7. doi: 10.1073/pnas.1318255110

40. Jost S, Altfeld M. Control of human viral infections by natural killer cells. *Annu Rev Immunol* (2013) 31:163–94. doi: 10.1146/annurev-immunol-032712-100001

41. Hong HS, Rajakumar PA, Billingsley JM, Reeves RK, Johnson RP. No monkey business: why studying NK cells in non-human primates pays off. *Front Immunol*. Citation: Albrecht C, Malzahn D, Brameier M, Hermes M, Ansari AA and Walter L. KIR and MHC class I polymorphisms and NK cell dysfunction. Front. Immunol. Citation: Albrecht C, Malzahn D, Brameier M, Hermes M, Ansari AA and Walter L. KIR and MHC class I polymorphisms and NK cell dysfunction. Front. Immunol. doi: 10.3389/fimmu.2014.00600

42. Naranbhai V, Altfeld M, Karim SSA, Ndung’u T, Karim QA, Carr WH. Changes for acute vs. persistent infections. *J Virol* (2011) 85:2424–33. doi: 10.1128/JVI.02277-09

43. Brunetta E, Hudspeth KL, Mavilio D. Pathologic natural killer cell subset redistribution in HIV-1 infection: new insights in pathophysiology and clinical outcomes. *J Leukoc Biol* (2010) 88(6):1119–30. doi: 10.1189/jlb.0410225

44. Brunetta E, Fogli M, Varchetta S, Bozzo L, Hudspeth KL, Marcenaro E, et al. The decreased expression of Siglec-7 represents an early marker of dysfunctional natural killer-cell subsets associated with high levels of HIV-1 viremia. *Blood* (2009) 114:382–30. doi: 10.1182/blood-2009-06-226332

45. LaBonte ML, McKay PF, Letvin NL. Evidence of NK cell dysfunction in SIV-infected rhesus monkeys: impairment of cytokine secretion and NKG2C/C2 expression. *J Immunol* (2006) 177(8):4119–30. doi: 10.4049/jimmunol.1001225

46. Welsh RM, Waggoner SN, NK cells controlling virus-specific T cells: rheostats for acute vs. persistent infections. *Virology* (2013) 435:37–45. doi: 10.1016/j.virology.2012.10.005

47. Choi EI, Reimann KA, Letvin NL. In vivo natural killer cell depletion during primary simian immunodeficiency virus infection in rhesus monkeys. *J Virol* (2008) 82:6758–61. doi: 10.1128/JVI.02277-07

48. Reeves RK, Rajakumar PA, Evans TJ, Conmoile M, Gillis J, Wong FE, et al. Gut inflammation and indoleamine deoxygenase inhibit IL-17 production and promote cytotoxic potential in NKp44+ mucosal NK cells during SIV infection. *Blood* (2011) 118:3832–130. doi: 10.1182/blood-2011-04-347260

49. Liyanage NPM, Gordon SN, Doster MN, Pegu P, Vaccari M, Shukur N, et al. Antiretroviral therapy partly reverses the systemic and mucosal distribution of NK cell subsets that is altered by SIVmac251 infection of macaques. *Virology* (2014) 450(0–451):359–68. doi: 10.1016/j.virology.2013.12.003

50. Rosner C, Kruse PH, Hermes M, Otto N, Walter L. Rhesus macaque inhibitory and activating KIR3D3D3 interact with MAMA-A-encoded ligands. *J Immunol* (2011) 186:2156–63. doi: 10.4049/jimmunol.1002634

51. Müh L, Krawczak M, Haaf ten P, Hunsmann G, Sauermann U. MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. *J Immunol* (2002) 169:3438–46. doi: 10.4049/jimmunol.169.6.3438

52. Guerra N, Michal F, Gati A, Gaudin C, Mishal Z, Escudier B, et al. Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction. *Blood* (2002) 100:2874–81. doi: 10.1182/blood-2002-02-0643

53. Sambrook JG, Bashirova A, Palmer S, Sims M, Trowsdale J, Abi-Rached L, et al. Single haplotype analysis demonstrates rapid evolution of the killer immunoglobulin-like receptor (KIR) loci in primates. *Genome Res* (2005) 15:25–35. doi: 10.1101/gr.2381205

54. Zhang Z-Q, Fu T-M, Casimiro DR, Davies M-E, Liang X, Schleif WA, et al. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. *J Virol* (2002) 76:12845–54. doi: 10.1128/JVI.76.24.12845-12854.2002

55. Mothe BR, Weinifurt JP, Yang C, Rehrauer W, Wilson N, Allen TM, et al. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. *J Virol* (2003) 77:2736–40. doi: 10.1128/JVI.77.7.2736-2740.2003

56. Colantonio AD, Bimber BN, Neidermyer WJ, Reeves RK, Alter G, Altfeld M, et al. Polymorphisms modulate peptide-dependent binding to an MHC Class I ligand with a Bw6 Motif. *PLoS Pathog* (2011) 7(2):e1001316. doi: 10.1371/journal.ppat.1001316

57. Schaffe JL, Colantonio AD, Neidermyer WJ, Dudley DM, Connoole M, O’Connor DH, et al. KIR3DL1 recognition of Bw6 ligands in the rhesus macaque: maintenance of Bw4 specificity since the divergence of apes and old world monkeys. *J Immunol* (2014) 192:1907–17. doi: 10.4049/jimmunol.1302883

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 03 October 2014; accepted: 07 November 2014; published online: 28 November 2014.

Citation: Albrecht C, Malzahn D, Brameier M, Hermes M, Ansari AA and Walter L (2014) Progression to AIDS in SIV-infected rhesus macaques is associated with distinct KIR and MHC class I polymorphisms and NK cell dysfunction. Front. Immunol. 5:600. doi: 10.3389/fimmu.2014.00600

This article was submitted to NK Cell Biology, a section of the journal Frontiers in Immunology. Copyright © 2014 Albrecht, Malzahn, Brameier, Hermes, Ansari and Walter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.